Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

Abstract

There was no pharmacokinetic-sequence interaction between C and P in this study. A clear dose-response relation with respect to response rate and survival was observed. The pharmacokinetic parameter P-T > or = 0.1 mumol/L was related to improved survival in this study.

Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells

“…In non-small cell lung cancer clinical studies, with chemotherapy naive patients, the sequence of carboplatin then taxol administration in combination treatments, showed no sequence-dependant toxicities or pharmacokinetic interactions. However it is not clear whether the different sequences affected response data (Giaccone et al 1995;Huizing et al 1997).…”

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

“…The data were obtained from several previously published studies in which patients received carboplatin both in high-dose as well as in conventionaldose regimens in combination with other chemotherapeutic agents [10][11][12][13][14]. All protocols were approved by the Committee of Medical Ethics of the Netherlands Cancer Institute and written informed consent was obtained from all patients.…”

“…Pretreatment serum creatinine levels were estimated by the kinetic Jaffé method (Hitachi systems, Roche Diagnostics, The Netherlands) in three studies [12][13][14] and in the first 32 patients of one study [11], while in the remaining patients [10,11] the compensated Jaffé method was used. To correct for the different methods used, the serum creatinine values obtained with the kinetic Jaffé method were retrospectively adjusted by subtracting 26 lM from the initial values as proposed and validated by the manufacturer (Roche Diagnostics, The Netherlands).…”

Cell-cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy

“…13,14 In lung cancer patients treated with these two agents, there were neither sequence-dependent toxicities nor pharmokinetic interactions. 29 In comparison, paclitaxel given prior to cisplatin had fewer hematologic side effects than when the drugs are administered in the reverse order. In this clinical study, the desired response rate differences relating to sequencing of this therapy were not evaluated.…”